| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | Chief Scientific Officer
1 company
Mark Erlander last filed a Form 4 in March 2025, as Chief Executive Officer at CRDF. Mark Erlander's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 24,481 shares of CRDF. Net of sales, the CRDF filings show accumulation of 22,958 shares.
Mark Erlander has 30 Form 4 filings on record from January 2016 to March 2025, all as Chief Executive Officer at Cardiff Oncology (CRDF), 2016–2025.
The 45 reported transactions were 15 option or other derivative awards, 13 option exercises, 13 tax withholdings and 4 open-market purchases.
Counted by filing, the open-market trades come to 4 purchases worth about $45K and no sales.
The largest open-market purchase was 10,000 shares of CRDF at an average $1.43 on November 25, 2022, about $14K. Twelve months later CRDF was down 12%.
Shares as reported in the last Form 4 for each company; the most recent is from March 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 25, 2022 | CRDF Cardiff Oncology, Inc. | Chief Executive Officer | Buy | 10,000 | $1.43 | $14,300.00 | +69.1% | +27.3% | -12.2% | |
| Mar 23, 2021 | CRDF Cardiff Oncology, Inc. | Chief Executive Officer | Buy | 965 | $10.34 | $9,979.74 | +7.1% | -22.3% | -75.7% | |
| May 14, 2020 | CRDF Cardiff Oncology, Inc. | Chief Executive Officer | Buy | 6,993 | $1.43 | $9,999.99 | +109.7% | - | - | |
| Dec 14, 2016 | CRDF Cardiff Oncology, Inc. | Chief Scientific Officer | Buy | 5,000 | $2.08 | $10,375.00 | New | - | - |